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Summary
Carfilzomib is a next-generation proteasome inhibitor that selectively and
irreversibly binds to its target. In clinical studies, carfilzomib has shown
efficacy in patients with relapsed and/or refractory multiple myeloma
(MM) and has demonstrated a tolerable safety profile. In this phase 2,
open-label, multicentre clinical trial, 35 patients with relapsed and/or
refractory MM following 1–3 prior therapies, including at least one bort-
ezomib-based regimen, received carfilzomib 20 mg/m2 in a twice-weekly,
consecutive-day dosing schedule for  12 monthly cycles. The best overall
response rate (ORR) was 171% and the clinical benefit response rate
(ORR + minimal response) was 314%. The median duration of response
was >106 months and the median time to progression was 46 months.
The most common adverse events were fatigue (629%), nausea (600%),
and vomiting (429%). No exacerbation of baseline peripheral neuropathy
was observed. Single-agent carfilzomib was generally well tolerated for up
to 12 treatment cycles and showed activity in patients with relapsed and/or
refractory MM who had received prior treatment with bortezomib. These
data, combined with an acceptable toxicity profile, support the potential
use of carfilzomib in patients with relapsed and/or refractory MM and war-
rant continued investigation of carfilzomib as single agent or in combina-
tion with other agents.
Keywords: Multiple myeloma, proteasome inhibitor, relapsed, refractory,
phase 2.
Multiple myeloma (MM) will affect an estimated 21 700
people and cause over 10 710 deaths in the United States
(US) in 2012 [American Cancer Society ACS (2012)]. The
US 5-year relative survival rate from 1999 to 2006 was just
39%, with a median survival of 4 years (Rajkumar, 2009; Sie-
gel et al, 2011a). Previously, therapy for relapsed and/or
refractory MM (i.e., patients who are either relapsed and
refractory OR relapsed or refractory) consisted primarily of
combination therapies based around melphalan, prednisone,
cyclophosphamide, dexamethasone or other broadly
cytotoxic agents (Kyle & Rajkumar, 2008); however,
treatment options and corresponding patient outcomes have
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greatly improved in the past decade following the
introduction of agents, such as thalidomide, lenalidomide
and liposomal doxorubicin (Plosker, 2008; Rajkumar, 2009;
Laubach et al, 2010). One notable therapy that has emerged
in recent years has been the proteasome inhibitor bortezomib
(Velcade®, Millennium Pharmaceuticals, Cambridge, MA,
USA), the first-in-class drug that validated the proteasome as
a target for therapeutic approaches to MM (Hideshima et al,
2001; Kane et al, 2003). Proteasome inhibitors such as bort-
ezomib are effective anti-cancer agents, as transformed cells
generally have a higher level of proteasome activity than dif-
ferentiated cells (Kanayama et al, 1991).
Although it is effective as an anti-myeloma drug, there are
limitations to the use of bortezomib, including development
of resistance and painful peripheral neuropathy (Mohty et al,
2010; Boyette-Davis et al, 2011). These adverse effects of
bortezomib have limited its use in some patients, for whom
there is a need for additional treatment options. A number
of modifications to the clinical dosing scheme for bortezomib
(eg, weekly dosing, subcutaneous (SC) administration) have
been evaluated in an effort to address these issues, with
encouraging results (Bringhen et al, 2010; Moreau et al,
2011). However, there is still a need for a next generation of
proteasome inhibitors with greater efficacy and improved tol-
erability profiles. One such novel proteasome inhibitor cur-
rently under development is carfilzomib (formerly PR-171;
Onyx Pharmaceuticals, South San Francisco, CA, USA).
Carfilzomib is a potent and highly selective proteasome
inhibitor that is structurally and mechanistically distinct from
bortezomib (Demo et al, 2007). Carfilzomib selectively and
irreversibly inhibits the chymotrypsin-like activity of the 20S
proteasome, necessitating de novo protein synthesis to restore
activity (Parlati et al, 2009). In preclinical studies, carfilzomib
demonstrated more potent proteasome inhibition and minimal
off-target activity against non-proteasomal proteases relative to
bortezomib (Demo et al, 2007). In addition, consecutive-day
dosing of carfilzomib was well-tolerated and led to prolonged
irreversible proteasome inhibition (Demo et al, 2007). Car-
filzomib has also shown a lack of histological or behavioural
neurotoxicity with chronic dosing in animals (Kirk et al, 2008;
Arastu-Kapur et al, 2011) and displayed cytotoxic activity
against bortezomib-resistant cell lines (Kuhn et al, 2007).
Early clinical studies testing carfilzomib in patients with
relapsed and/or refractory haematological malignancies
including MM have been encouraging, with rapid responses
beginning shortly after the onset of therapy, primarily mild
or moderate haematological toxicities, and low rates of
peripheral neuropathy (PN) (Alsina et al, 2007; O’Connor
et al, 2009; Singhal et al, 2011). A minimal effective dose of
15 mg/m2 has been established. (O’Connor et al, 2009).
Durable responses (from >90 to >280 d) have been achieved
in patients using a twice-weekly, consecutive-day dosing
schedule, and responses were observed in patients who had
failed bortezomib therapy, treatment with immunomodula-
tory agents, and stem cell transplant (Alsina et al, 2007).
Following these promising results, 2 phase 2 studies were
initiated to evaluate single-agent carfilzomib in patients with
relapsed and refractory MM following at least two lines of
therapy (PX-171-003) and in patients with relapsed and/or
refractory MM following 1–3 prior therapies (PX-171-004).
The 003 study, from which the results have been submitted
to the US Food and Drug Administration for regulatory
review and accelerated approval of carfilzomib, involved a
larger population of patients (N = 266) (Siegel et al, 2010).
The 004 study is a smaller study originally designed to inves-
tigate the impact of carfilzomib treatment in less heavily-
treated patients. The results presented here are from the
analysis of the lower dose, first cohort of a larger study in
patients who had previously been exposed to bortezomib
(Fig 1). Following an amendment to the study, a separate
cohort that included only bortezomib-naı¨ve patients was ini-
tiated to investigate a higher dose of carfilzomib; the data for
bortezomib-naı¨ve patients were analysed independently and
published separately (Vij et al, 2012).
Methods
Study design and eligibility
This was a phase 2 multicentre, open-label, single-arm study
registered at Clinical Trials.gov (NCT00530816). Written
informed consent was obtained from all enrolled patients in
accordance with the Declaration of Helsinki, and the study
was approved by the Institutional Review Board of each par-
ticipating centre.
Patients with measurable relapsed and/or refractory MM
who were 18 years of age or older were eligible to participate
in this study. Measurable disease was defined as either or
both of the following: serum M-protein  10 g/l and/or
urine M-protein  200 mg/24 h. Prior to an amendment to
• Measurable multiple myeloma 
• ECOG performance status 0–2 
• Responsive to ≥1 line of prior therapy 
• Relapsed and/or refractory following 1–3 
prior treatment regimens 
PX-171-004 (NCT00530816) 
Study population = 164 
Fig 1. PX-171-004 Study Design. ECOG, Eastern Cooperative Oncol-
ogy Group.
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the protocol, four patients were permitted to enter the study
with disease measurable by serum free light chain (sFLC)
only. Key inclusion criteria were: Eastern Cooperative Oncol-
ogy Group Performance Status (ECOG PS) of 0–2, respon-
sive [i.e., achieved minimal response (MR) or better] to
standard first-line therapy, and relapsed or relapsed and
refractory after 1–3 prior therapeutic regimens (including at
least one bortezomib-containing regimen). Refractory disease
was defined as  25% response or progressive disease (PD)
either during therapy or within 60 d after completion of the
last therapy. Induction therapy, stem cell transplant, and
planned maintenance were considered as one regimen.
Patients were also required to have: total white blood cell
(WBC) count  20 9 109/l, absolute neutrophil count
(ANC)  10 9 109/l, haemoglobin  80 g/l, platelet count
 50 9 109/l, creatinine clearance (CrCl)  30 ml/min, and
adequate hepatic function.
Excluded from the study were patients who: had received
glucocorticoid therapy (prednisone >10 mg/d or equivalent)
or chemotherapy with an approved or investigational anti-
cancer treatment (including corticosteroid therapy) within
the 3 weeks prior to first dose; received radiation therapy or
immunotherapy in the 4 weeks prior to first dose or received
localized radiation therapy within 1 week prior to first dose;
participated in an investigational therapeutic study within
3 weeks or 5 drug half-lives prior to first dose (whichever
time was greater); or had prior treatment with carfilzomib.
Other exclusion criteria included cardiovascular disease
(including congestive heart failure [New York Heart Associa-
tion Grade III or IV], symptomatic ischaemia, uncontrolled
conduction abnormalities, and myocardial infarction); acute
active infection requiring systemic antibiotics, antivirals, or
antifungals within 2 weeks prior to first dose; human immu-
nodeficiency virus seropositivity or active hepatitis A, B, or C
infection; or significant neuropathy (Grade 3, 4, or Grade 2
with pain) at the time of the study initiation.
Treatment
Intravenous (IV) carfilzomib (20 mg/m2) was administered
over a period of 2–10 min on days 1, 2, 8, 9, 15, and 16 of
every 28-d cycle for up to 12 cycles. During the first cycle,
prophylactic dexamethasone at a dose of 4 mg/d was admin-
istered prior to each dose of carfilzomib to ameliorate fever,
chills, shortness of breath, and/or rigors. In phase 1 studies,
these symptoms had been observed in small subsets of study
patients in Cycle 1 and occasionally in Cycle 2. In the cur-
rent study, if any of these treatment-related effects were
observed during treatment after dexamethasone had been
discontinued, oral (PO) or IV dexamethasone 4 mg was per-
mitted to be re-administered prior to subsequent doses of
carfilzomib. Carfilzomib doses were held or reduced to 15
and 11 mg/m2 in response to certain adverse events (AEs),
and following resolution, patients were permitted to resume
treatment at the same dose level (eg, for reversible haemato-
logical AEs) or a reduced dose level, depending on the AE.
No more than 2 dose reductions were permitted before
removal from the study. Patients completing 12 cycles of
treatment with carfilzomib were eligible to continue receiving
carfilzomib on extension study PX-171-010 (NCT00884312).
Assessment of response and safety
The response-evaluable population comprised patients who
had completed at least one cycle of treatment with carfilzo-
mib, underwent at least one post-baseline response assess-
ment, and had disease measurable by protein electrophoresis.
Overall response rate (ORR) to carfilzomib included strin-
gent complete response (sCR), complete response (CR), very
good partial response (VGPR), and partial response (PR).
The primary endpoint of ORR was based on response-evalu-
able subset population, which excluded four patients whose
disease was followed by sFLC measurement only. Secondary
endpoints were based on the whole response-evaluable popu-
lation and included: the best ORR throughout the treatment
period and clinical benefit response (CBR) rate
(ORR + MR); duration of response (DOR), defined as time
from first evidence of PR or better, i.e., first observation of
PR that is subsequently confirmed to PD or death without
PD; time to progression (TTP), defined as time from study
entry (first dose of carfilzomib) to PD; and overall survival
(OS, defined as time from first dose of carfilzomib to date of
death). Progression-free survival (PFS, defined as time from
start of treatment to PD or death due to any cause) was also
included. Additional exploratory efficacy endpoints were
duration of clinical benefit (defined as the time from first
confirmed MR or higher to the first confirmed PD or death
without PD) and duration of MR.
Patients were evaluated for response on Day 15 of Cycle 1,
Day 1 of Cycles 2–12, and at the end of the study. Responses
and progression were assessed according to the International
Myeloma Working Group’s Uniform Response Criteria (Du-
rie et al, 2006) for all except MR, which was assessed using
the European Group for Blood and Marrow Transplantation
(EBMT) criteria (Blade et al, 1998). In brief, MR was defined
in the protocol as reduction of M-protein  25% and <50%
in serum or  50% and <90% in urine, maintained for
6 weeks (MR was considered confirmed with an interval of
at least 4 weeks between measurements for patients with an
observation of PD or death at least 6 weeks from the first
MR observation). Responses were reviewed, confirmed, and
adjudicated by an independent review committee consisting
of four individuals not associated with the trial (three clini-
cians as voting members and one non-voting secretary).
Independent Review Committee (IRC) assessments were doc-
umented in the case report form (CRF) and entered in a
database maintained separately from the clinical database.
Discordant cases between the IRC and investigator were re-
reviewed by the IRC, which was also documented in the
CRF.
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The incidence and severity of AEs were also assessed. The
safety population included all patients who received at least
one dose of carfilzomib. Safety assessments included AEs and
serious AEs (SAEs), laboratory values, and vital signs. AEs
were summarized based on the number and percentage of
patients experiencing events according to the Medical Dictio-
nary for Regulatory Activities (MedDRA®, Chantilly, VA,
USA) AE dictionary system organ class and preferred term.
The National Cancer Institute Common Terminology Crite-
ria for Adverse Events, version 3 (http://ctep.cancer.gov/pro-
tocolDevelopment/electronic_applications/docs/ctcaev3.pdf),
was used to grade AEs.
Because of the significant rates of PN historically observed
with the use of bortezomib, the incidence and severity of PN
was carefully evaluated in this study. Detailed individual neu-
ropathy histories were collected at screening, and compre-
hensive neurophysical examinations were conducted. In
addition, patients were required to complete a PN-related
quality of life (QoL) survey, the Functional Assessment of
Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity
(FACT/GOG-NTx) version 4.0 (Huang et al, 2007). Following
every two cycles of treatment, neurological exams were con-
ducted and patients completed the FACT-GOG/NTx question-
naire.
Statistical analyses
Descriptive statistics, including 2-sided 95% confidence inter-
vals (CIs), were used to summarize all study endpoints. All
statistical analyses were performed using SAS® version 9.1 or
later (SAS Institute, Inc., Cary, NC, USA). Best ORR was
determined based on a 2-sided 95% CI for evaluable patients
whose best response was classified as sCR, CR, VGPR, or PR.
Analysis of ORR was performed in subgroups defined
according to a number of covariates as exploratory analyses
by patient baseline characteristics of age, ECOG PS, Interna-
tional Staging System (ISS) for MM stage (Greipp et al,
2005), and serum b2-microglobulin concentration. Cytoge-
netic/fluorescent in situ hybridization (FISH) prognostic
markers of high-risk disease were defined per Mayo Stratifi-
cation of Myeloma and Risk-adapted Therapy (mSMART)
criteria (Dispenzieri et al, 2007) analysed by either FISH [for
del17p, t(4;14), or t(14;16)] or by metaphase cytogenetics
(for del13 or hypodiploidy). ORR was estimated within each
subgroup along with its 95% exact binomial CIs. Analysis for
time-to-event secondary endpoints (PFS, TTP, DOR, and
OS) was performed by preparing Kaplan-Meier estimates for
quartiles including median and Kaplan-Meier curves. Also
generated were 2-sided 95% CIs for the quartiles. The event-
free rate was estimated for several time points (e.g.,
9 months).
Simple descriptive statistics were used to summarize the
AE profile of carfilzomib based on the number and percent-
age of patients experiencing system organ class events.
Changes in clinical safety laboratory values and vital signs
were summarized descriptively for each scheduled and
unscheduled time point. Changes were calculated relative to
the values collected at baseline and on the first day of each
treatment cycle.
Results
Patient population
A total of 35 bortezomib-treated patients from 17 centres
enrolled in this study between September 2007 and Novem-
ber 2008 with a data cutoff of November 2010. All patients
received at least one dose of carfilzomib and therefore were
evaluable for both safety and efficacy. The median age was
63 years (range 40–77) and the median time from diagnosis
was 36 years (range 12–132) (Table I). A high tumour bur-
den was demonstrated by an ISS stage of II or III in 429%
of patients. A significant proportion of patients had poor/
unfavourable markers by cytogenetic or FISH analysis
(257%), and the median serum b2-microglobulin concentra-
tion at baseline was 33 mg/l (range 16–98). More than half
of all patients had active PN at baseline: Grade 1 in 16
patients (457%) and Grade 2 in three patients (86%). At
the time of study entry, a large proportion of patients also
had active haematological abnormalities, including anaemia
(857%), neutropenia (571%), and thrombocytopenia
(286%), all of Grade 1/2 in severity with the exception of
one patient with Grade 3 thrombocytopenia.
Patients had received a median of 30 prior therapies
(range 1–13)(Table II). Five (143%) patients received four
or more prior regimens, and all patients had been previously
treated with bortezomib. More than half of all patients (20;
571%) received bortezomib in their treatment regimen
immediately preceding study entry. Seven patients (200%)
were refractory to bortezomib at any time prior to participat-
ing in this study, and 22 patients (629%) had disease that
was refractory to their last therapy regardless of drug. The
majority of patients (971%) had previously received cortico-
steroid therapy; other common treatments included alkylat-
ing agents (886%), thalidomide (686%), and lenalidomide
(371%), and 800% of the patients enrolled had undergone
autologous stem cell transplant.
Efficacy
All 35 patients were included in the response-evaluable pop-
ulation, for which the best ORR was 171% as determined by
an independent central assessment (1 CR, 1 VGPR, and 4
PR), and the CBR rate was 314% (Table III). Responses
were observed even in those patients with more severe dis-
ease at baseline; >10% ORR was reported in subgroups anal-
ysed by patient baseline characteristics of ECOG PS and ISS
stage prognostic markers, as well as poor/unfavourable mark-
ers characterized by cytogenetic analysis (six patients) or
FISH analysis (three patients) (Table IV). Although there
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were some differences in absolute numbers (e.g., the ORRs
between ISS Stages I, II, and III), the small numbers of
patients in each subgroup, along with the wide confidence
intervals, precluded any firm conclusions to be drawn from
differences between or within subgroups. In the response-
evaluable subset population (N = 31), in which patients with
disease measured by sFLC only were excluded, ORR was
161% (1 CR, 1 VGPR and 3 PR) as determined by an inde-
pendent central assessment.
Responses were fairly rapid, with a median time to
response (TTR) of 14 months to achieve PR and
Table I. Patient baseline characteristics.
Characteristic
Carfilzomib
20 mg/m2
(N = 35)
Median age, years (range) 63 (40–77)
Male gender 18 (514)
Median time from diagnosis, years (range) 36 (12–132)
Immunoglobulin subtype, n (%)
IgG 24 (686)
IgA 5 (143)
IgD 1 (29)
Unknown/Missing 5 (143)
Light chain subtype, n (%)
Kappa 23 (657)
Lambda 12 (343)
ECOG PS, n (%)
0 15 (429)
1 or 2 19 (543)
ISS Stage, n (%)
I 19 (543)
II 8 (229)
III 7 (200)
Baseline evaluation, n (%)
Peripheral neuropathy Grade 1 19 (543)
Diabetes 5 (143)
CrCl <50 ml/min 4 (114)
b2-microglobulin, mg/l (range) 33 (16–98)
Cytogenetic/FISH prognostic markers, n (%)
Normal/Favourable 25 (714)
Unfavourable 9 (257)
Ig, immunoglobulin; ECOG PS, Eastern Cooperative Oncology
Group performance status; ISS, International Staging System; CrCl,
creatinine clearance; FISH, fluorescence in situ hybridization.
Table II. Prior therapies.
Carfilzomib
20 mg/m2
(N = 35)
Median number of prior therapies (range) 30 (1–13)
Prior therapy, n (%)
Bortezomib 35 (1000)
Bortezomib in last regimen 20 (571)
Thalidomide 24 (686)
Lenalidomide 13 (371)
Thalidomide or lenalidomide 27 (771)
Corticosteroid 34 (971)
Alkylating agent 31 (886)
Anthracycline 11 (314)
Stem cell transplant 28 (800)
Refractory status, n (%)
To bortezomib in any prior regimen 7 (200)
To last therapy,* n (%) 22 (629)
*Most patients received a combination regimen as their last therapy.
Table III. Best overall response (response-evaluable population).
Carfilzomib
20 mg/m2
(N = 35)
Best response, n (%)*
CR 1 (29)
VGPR 1 (29)
PR 4 (114)
MR 5 (143)
SD 13 (371)
PD 10 (286)
ORR (sCR + CR + VGPR + PR) 6 (171)
CBR (ORR + MR) 11 (314)
CR, complete response; VGPR, very good partial response; PR, par-
tial response; MR, minimal response; SD, stable disease; PD, progres-
sive disease; ORR, overall response rate; CBR, clinical benefit
response.
*Includes four patients whose disease was followed by sFLC, one of
whom had a confirmed response.
Table IV. Overall response rate (ORR) of baseline characteristic sub-
group.*
n ORR,% 95% CI
Overall 35 171 66–337
Baseline characteristic
Age group
<65 years 21 95 12–304
 65 years 14 286 84–581
ECOG PS
0 15 267 78–551
1 or 2 19 105 13–331
ISS Stage
I 19 158 34–396
II 8 250 32–651
III 7 143 04–579
Cytogenetic/FISH prognostic markers
Normal/favourable 25 160 45–361
Poor/unfavourable 9 111 03–482
ECOG PS, Eastern Cooperative Oncology Group performance status;
ISS, International Staging System; FISH, fluorescence in situ hybrid-
ization.
*Response-evaluable population.
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10 month to achieve MR. The median DOR was
>106 months with four out of the six patients with a DOR
of 106 months or longer. A more precise estimate of the
median DOR could not be determined as four of the six
patients with responses had their DOR censored at the close
of the study (Table V). Median duration of clinical benefit
was 106 months and median duration of MR was
79 months. The median TTP was 46 months (95% CI: 19–
111) (Fig 2) and the median PFS was 46 months (95% CI:
21–111). Median OS was calculated to be 299 months;
however, survival data remain immature and neither the
upper nor lower limit of 95% CI could be estimated as of
the data cutoff.
Safety
The safety population included all 35 patients enrolled in the
study. Patients started a median of four cycles of carfilzomib
(range 1–12), and nine patients (257%) completed 12 cycles
of carfilzomib therapy. Although no patients from this study
entered the PX-171-010 extension protocol, 1 patient contin-
ued to receive carfilzomib treatment on a single-patient
extension protocol for an additional 11 months.
Carfilzomib was generally well tolerated. The most fre-
quent AEs were fatigue (629%), nausea (600%), vomiting
(429%), diarrhoea, and dyspnea (both 371%) (Table VI).
Twenty patients (571%) experienced at least one severe
(Grade  3) AE, the majority of them (15/20) Grade 3. The
most common Grade 3/4 AEs were haematological, including
thrombocytopenia (200%), anaemia (143%), and neutrope-
nia (114%). Treatment-related AEs occurred in all patients
and the most common were nausea (514%), fatigue
(486%), increased serum creatinine (343%), diarrhoea
(314%), vomiting (314%), dyspnea (286%), thrombocyto-
penia (286%), and anaemia (257%).
Of the 26 patients that discontinued early, 16 patients dis-
continued due to disease progression and six patients due to
treatment-emergent AEs; the only AE leading to discontinua-
tion for more than one patient was hypercalcaemia (two
patients). Other reasons for discontinuation were physician
Table V. Time to progression, time to response, and duration of
response.*
Carfilzomib
20 mg/m2
(N = 35)
Median TTP, months (95% CI) 46 (19–111)
Median TTR, months (95% CI)
PR (ORR) 14 (05–19)
MR (CBR) 10 (05–67)
Median DOR, months (95% CI)
PR (ORR) NE (106–NE)
MR (CBR) 106 (72–NE)
MR 79 (58–146)
NE, not estimated due to censoring; TTP, time to progression; TTR,
time to response; DOR, duration of response; 95% CI, 95% confi-
dence interval; PR, partial response; MR, minimal response; ORR,
overall response rate; CBR, clinical benefit response.
*Response-evaluable population.
Table VI. Safety population treatment-emergent adverse events of all
grades ( 20%) or Grade 3 ( 5%).
Treatment-emergent adverse event
Carfilzomib
20 mg/m2
(N = 35)
All Grades
n (%)
Grade 3
n (%)
Haematological
Anaemia 12 (343) 5 (143)
Thrombocytopenia 11 (314) 7 (200)
Neutropenia 9 (257) 4 (114)
Lymphopenia 6 (171) 2 (57)
Non-haematological
Fatigue 22 (629) 1 (29)
Nausea 21 (600) 1 (29)
Vomiting 15 (429) 1 (29)
Dyspnea 13 (371) 2 (57)
Diarrhoea 13 (371) 0 (0)
Upper respiratory infection 12 (343) 2 (57)
Increased serum creatinine 12 (343) 1 (29)
Increased alanine aminotransferase 10 (286) 0 (0)
Headache 9 (257) 1 (29)
Hypoesthesia 9 (257) 0 (0)
Pyrexia 9 (257) 0 (0)
Asthenia 8 (229) 1 (29)
Constipation 8 (229) 0 (0)
Cough 8 (229) 0 (0)
Dizziness 7 (200) 0 (0)
Increased aspartate aminotransferase 7 (200) 0 (0)
Pain 7 (200) 0 (0)
Hypertension 6 (171) 2 (57)
Hypercalcaemia 5 (143) 2 (57)
Pneumonia 3 (86) 3 (86)
Epiglottitis 2 (57) 2 (57)
0
25
50
75
100
22·52·5
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s 
fr
ee
fr
om
 p
ro
gr
es
si
on
Months from start of treatment
20·017·515·012·510·07·55·00·0
Censored observations
Confidence interval
Number at risk:
BTZ treated
35 19 13 11 9 5 3 1 1
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discretion and near complete remission (one patient each) as
well as patient decision to come off study or withdrew con-
sent (one patient each). No deaths occurred on study (inclu-
sive of 30 d of last carfilzomib dose). Nearly half of the
patients (457%) received the protocol-specified dosing sche-
dule on time and 629% received doses of 90–100% of the
relative dose intensity specified in the protocol. Four patients
had dose reductions due to AEs, although three of these
patients were successfully re-escalated to the 20 mg/m2 dose.
During the study 6 (171%) patients experienced neuropa-
thy-related treatment-emergent AEs; the majority of PN
reports were Grade 1 and considered not related to carfilzo-
mib treatment (four patients). Additionally there was one
patient with Grade 2 and one patient with Grade 3 (both pos-
sibly related to treatment) and no reports of Grade 4 PN.
There were no dose reductions or discontinuations due to PN,
which is especially notable as 543% of all study patients had
Grade 1-2 PN at baseline. Moreover, prolonged treatment
with carfilzomib as seen in this study was not associated with
any significant increase in neuropathy, as supported by the
absence of a meaningful change from baseline to the last
assessment (n = 30) on the FACT/GOG-NTx results.
Discussion
In this study, the best ORR for the response-evaluable
population was 171% and the CBR was 314%. Additional
statistical testing between subgroups was not performed due
to the small numbers within subgroups; however, responses
of at least 10% were observed even in high-risk patients and
those with more severe disease, including poor/unfavourable
cytogenetics and ISS stage III based on the subgroup
analyses. These results indicate single-agent activity in this
population and are interesting because of the very limited
data available on retreatment with monotherapies in patients
with MM refractory to bortezomib (Mohty et al, 2012; van
de Donk et al, 2011). Because the number of patients in this
study was relatively small, caution must be used in
interpreting the results. However, the results of this study are
comparable to those from previous carfilzomib studies with
patients who had similar medical and treatment histories
(Alsina et al, 2007; Siegel et al, 2010).
The majority of carfilzomib doses in this study were
administered at the 20 mg/m2 level. Subsequent studies have
demonstrated the tolerability of higher doses including
27 mg/m2 on the same schedule and 56 mg/m2 when given
as a 30-min infusion (Siegel et al, 2010; Papadopoulos et al,
2011). Based on the results of other carfilzomib studies with
a dosing regimen of 27 mg/m2, including the 003-A1 study
and the independently analysed bortezomib-naı¨ve cohorts
from the 004 study, it is likely that increased anti-MM
activity would be observed even at higher dose levels as a
single agent (Siegel et al, 2010; Vij et al, 2010, 2012).
At a median follow-up of 134 months (95% CI: 89–
166), the median TTP was 46 months (95% CI: 19–111).
In part, this short median TTP is the result of early disease
progression in approximately 50% of patients, most probably
due to advanced disease at the time of study entry. For
patients remaining on study for more than four cycles,
progression events were often substantially delayed, a finding
consistent with the promising DOR seen in both patients
with PR and those with MR. The median DOR of
79 months (95% CI: 58–146) reached for patients
experiencing MR suggests that MR may be an equally valid
response endpoint and supports the concept that sustained
MR is associated with a clinically meaningful benefit
(Richardson et al, 2005; Niesvizky et al, 2008). These results
reinforce the suggestion of durable disease control with
carfilzomib monotherapy for a significant number of heavily
pretreated patients in this study.
Carfilzomib treatment was generally tolerable, with the
majority of patients receiving carfilzomib at the planned dose
and according to schedule. The fact that patients started a
median of four cycles of treatment correlates well with median
time to response and indicates that patients are able to tolerate
carfilzomib for a long enough interval to see evidence of
response. Reinforcing the tolerability profile of carfilzomib
from other studies (Siegel et al, 2011b; Singhal et al, 2011),
25·7% of patients completed a full 12 cycles of treatment and
one patient continued on a single-patient extension protocol.
The most common treatment-related AEs were gastrointes-
tinal (nausea, diarrhoea, vomiting, and constipation), consti-
tutional (fatigue), respiratory (dyspnea), and myelosuppressive
(thrombocytopenia, anaemia, and neutropenia). When com-
pared with a larger study of carfilzomib with a similar but
more heavily treated bortezomib-relapsed and refractory pop-
ulation (PX-171-003) (Siegel et al, 2010), the overall AE rates
were comparable, although certain toxicities were reported less
frequently in this study, namely haematological AEs Grade
3. Additionally, although an actual comparison cannot be
made due to the differences in trial sizes and patient popula-
tions, toxicity compared relatively favourably to bortezomib—
in the Assessment of Proteasome Inhibition for Extending
Remissions (APEX) trial comparing treatment of bortezomib
and dexamethasone in patients with relapsed MM, 9% of
patients completed the planned bortezomib therapy compared
with the 257% here, and 37% had AEs resulting in discontinu-
ation of bortezomib compared with the 171% that discontin-
ued due to an AE here (Richardson et al, 2005).
PN is a common occurrence in patients with MM and is
both caused and exacerbated by treatment with bortezomib
and thalidomide. PN has been reported in up to 70% of
patients treated with thalidomide and approximately 37% of
patients treated with bortezomib (Mohty et al, 2010).
Therefore, the occurrence of PN was carefully monitored in
this study. The incidence of neuropathy at baseline for this
study was >50%, but exacerbations were not observed upon
carfilzomib treatment. Similarly, previous studies have found
that baseline PN does not impact the efficacy and tolerability
of carfilzomib (Martin et al, 2010). Additionally, patients’
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self-reported experiences and quality of life in the current
study were minimally impacted from the initiation of the
study through to their last assessment, further supporting the
PN-specific tolerability of this agent.
In summary, single-agent carfilzomib at 20 mg/m2
achieved significant responses in this heavily pre-treated pop-
ulation, including treatment with bortezomib and the immu-
nomodulatory agents thalidomide and lenalidomide.
Treatment with carfilzomib was well tolerated for up to 12
cycles, and a lack of significant toxicities supports the use of
single-agent carfilzomib or potential combination regimens.
The results of the larger phase 2 study of carfilzomib therapy
in heavily pretreated patients with relapsed and refractory
MM, including a significant proportion of patients previously
treated with bortezomib (PX-171-003-A1, NCT00511238),
further demonstrate the efficacy of carfilzomib in this popu-
lation (Siegel et al, 2010, 2011c). Ongoing studies are investi-
gating the use of carfilzomib in combination with other
agents and its use in patients with newly diagnosed MM.
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